Adverse Reactions to Voriconazole
Open Access
- 15 October 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (8), 1241-1244
- https://doi.org/10.1086/424662
Abstract
Voriconazole is a new antifungal agent effective in the treatment of invasive aspergillosis. Interpatient variation in plasma concentrations is considerable—more than 100-fold. We describe 3 patients with diverse manifestations of toxicity (e.g., hallucinations, hypoglycemia, electrolyte disturbance, and pneumonitis) possibly attributable to high voriconazole concentrations. Measurement of plasma concentrations could be helpful in optimizing voriconazole dosages.Keywords
This publication has 6 references indexed in Scilit:
- Safety of Voriconazole and Dose IndividualizationClinical Infectious Diseases, 2003
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazoleClinical and Experimental Dermatology, 2001
- Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in PlasmaAntimicrobial Agents and Chemotherapy, 2000
- The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*Clinical Pharmacology & Therapeutics, 1995